S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

PTN Palatin Technologies Inc New

0.00

0.00 (0.00%)

- - Closed

Delayed by 15 minutes

Form 424B5 - Prospectus [Rule 424(b)(5)]

null

Palatin Technologies (AMEX:PTN)
Historical Stock Chart
From Jun 2024 to Jul 2024

Click Here for more Palatin Technologies Charts.

Palatin Technologies (AMEX:PTN)
Historical Stock Chart
From Jul 2023 to Jul 2024

Click Here for more Palatin Technologies Charts.

Palatin Technologies Inc New News

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
Friday 21 June 2024 (1 week ago) • PR Newswire (US)

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
Thursday 20 June 2024 (2 weeks ago) • PR Newswire (US)

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
Wednesday 12 June 2024 (3 weeks ago) • PR Newswire (US)

Form 8-K - Current report
Wednesday 15 May 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 15 May 2024 (2 months ago) • Edgar (US Regulatory)

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Wednesday 15 May 2024 (2 months ago) • PR Newswire (US)

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
Thursday 9 May 2024 (2 months ago) • PR Newswire (US)

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
Thursday 2 May 2024 (2 months ago) • PR Newswire (US)

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
Tuesday 30 April 2024 (2 months ago) • PR Newswire (US)

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Monday 8 April 2024 (3 months ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 8 March 2024 (4 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 5 March 2024 (4 months ago) • Edgar (US Regulatory)

More Palatin Technologies Inc New News Articles

Vnv Global Ab (publ)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions